Driven by the potential to treat the root cause of diseases, including rare clinical conditions and those that were previously deemed incurable, the gene therapies pipeline is growing, and the market anticipated to witness substantial growth, till 2030
Roots Analysis has announced the addition of “Gene Therapy Market 2020-2030” report to its list of offerings.
Success of approved gene therapies has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of gene therapies to treat diverse disease indications is considered among the most prominent drivers of this market. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.
Get Detailed Report: https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html
Key Market Insights
Around 800 gene therapies are currently being developed across different stages
Apart from 10 approved products, most of the aforementioned therapies (65%) are in the early stages of development (discovery / preclinical), while the rest are being evaluated in clinical trials. It is worth mentioning that more than 40% of clinical stage candidates are intended for the treatment of oncological disorders.
Over 65% of innovator companies focused on gene therapy development, are based in North America
Interestingly, more than 75 players based in the same region, are start-ups, while over 35 are mid-sized players, and 10 are large and very large firms. Since the majority of gene therapy developers are headquartered in the US, it is considered a key RD hub for such advanced therapy medicinal products.
There are 400+ registered gene therapy focused clinical trials, worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of 12% during the period 2015-2020. Of the total number of trials, close to 25% have already been completed, and 35% claim to be actively recruiting.
USD 25.4 billion has been invested by both private and public investors, since 2015
So far, a significant proportion of the capital raised has been through secondary offerings (USD 12.9 billion). On the other hand, around USD 5 billion was invested by venture capital investors, representing 20% of the total amount.
Close to 20,000 patents have been filed / published related to gene therapies, since 2016
Around 30% of the total number of applications were related to gene editing-based therapies, while the remaining were associated with gene therapies. Further, majority of the patent assignees were industry players, however, the contribution of non-industry players in the overall patent filing activity has increased considerably (CAGR of 16%), over the past few years.
There have been several mergers and acquisitions in this market during the period 2015-2019
In fact, MA activity is reported to have increased at a CAGR of more than 40%. Key drivers of the acquisitions mentioned in the report include, therapeutic area expansion, access to a novel technology / platform, drug class consolidation and drug class expansion.
North America and Europe are anticipated to capture over 90% of the market share, in terms of sales revenues, in 2030
In vivo gene therapies currently represent a significant share of the market, and this trend is unlikely to change in the foreseen future, as several such candidates are being evaluated in late stages. In addition, more than 130,000+ patients are projected to use gene therapies in 2030 and the demand for gene therapies is expected to grow at an annualized rate of 29% and 31% during the periods 2020-2025 and 2025-2030, respectively.
Request for Customization: https://www.rootsanalysis.com/reports/268/request-customization.html
Key Questions Answered
- Who are the leading players engaged in the development of gene therapies?
- How many gene therapies are presently being evaluated across different stages of development?
- What are various diseases targeted by gene therapies?
- What are the key technology platforms that are either available, or being developed for gene therapy discovery and production?
- What kind of vectors are commonly used for the delivery of gene therapies?
- What are the key regulatory guidelines governing the approval of gene therapies, across various geographies?
- What kind of pricing models and reimbursement strategies are currently used by gene therapy developers?
- What kind of contract services are offered related to gene therapies? Who are the key players in this market?
- What are the drivers of the MA activity in this market?
- What kind of investors have stake in the gene therapy market?
- What kind of commercialization strategies are used by gene therapy developers?
- How is the current and future market opportunity likely to be distributed across key market segments?
The USD 14.6 billion (by 2030) financial opportunity within the gene therapy market has been analyzed across the following segments:
- Therapeutic approach
- Gene augmentation
- Oncolytic therapy
Type of gene therapy
- Ex vivo
- In vivo
Type of vector used
- Adeno associated virus
- Herpes simplex virus
- Plasmid DNA
Key therapeutic areas
- Autoimmune disorders
- Cardiovascular diseases
- Dermatological disorders
- Genetic disorders
- Hematological disorders
- Metabolic disorders
- Muscle-related diseases
- Oncological disorders
- Ophthalmic diseases
Route of administration
Key geographical regions
- North America
The report features inputs from eminent industry stakeholders, according to whom, gene therapies exhibit the potential to become a promising alternative for the treatment of genetic disorders. The report includes detailed transcripts of discussions held with the following experts:
- Adam Rogers (CEO, Hemera Biosciences)
- Al Hawkins (CEO, Milo Biotechnology)
- Buel Dan Rodgers (Founder CEO, AAVogen)
- Christopher Reinhard (CEO Chairman, Gene Therapeutics (previously known as Cardium Therapeutics))
- Michael Triplett (ex-CEO, Myonexus Therapeutics)
- Robert Jan Lamers (ex-CEO, Arthrogen)
- Ryo Kubota (CEO, Chairman President, Acucela)
- Tom Wilton (ex-CBO, LogicBio Therapeutics)
- Jeffrey Hung (CCO, Vigene Biosciences)
- Cedric Szpirer (Executive Scientific Director, Delphi Genetics)
- Marco Schmeer (Project Manager) and Tatjana Buchholz (ex-Marketing Manager, PlasmidFactory)
- Molly Cameron (Corporate Communications Manager, Orchard Therapeutics)
Request for PDF Sample: https://www.rootsanalysis.com/reports/268/request-sample.html
The research includes brief profiles of key players (listed below) engaged in the development of gene therapies; each profile features an overview of the therapy, current development status, clinical trials and its results (if available), target indication, route of administration, and recent developments (if available).
- Abeona Therapeutics
- bluebird bio
- Castle Creek Biosciences
- CG Oncology
- Freeline Therapeutics
- Inovio Pharmaceuticals
- Kolon TissueGene
- Krystal Biotech
- Neurophth Therapeutics
- OncoSec Immunotherapies
- Orchard Therapeutics
- Sangamo Therapeutics
- Spark Therapeutics
- uniQure Biopharma
- VBL Therapeutics
Also have a Look on Our Upcoming Research Reports
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at email@example.com
Roots Analysis Private Limited
+1 (415) 800 3415